Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening Products

A Cancer Gene Switch For Repairing Damaged DNA
Scientists at the Medical Research Council Laboratory of Molecular Biology uncover how an important cancer gene, BRCA1, works by increasing the accuracy with which broken DNA is repaired. Women who inherit a faulty version of the BRCA1 gene are at a higher risk of developing breast or ovarian cancer.
generic viagra online
Induction Of Labour After 37 Weeks Recommended For Women With Gestational Hypertension/Mild Pre-Eclampsia (Hypitat Study)
Pregnant women with mild hypertensive disorders such as high blood pressure/mild pre-eclampsia^ should have their labour induced once they complete 37 weeks of their pregnancy. This is the conclusion of the HYPITAT study, published in an Article Online First and in an upcoming edition of The Lancet, written by Dr Corine M Koopmans, Department of Obstetrics and Gynaecology, University Medical Centre Groningen, Netherlands, and colleagues.
News of the day
No Blue Dog Deal In House As Compromise Proves Elusive
House leaders and the fiscally conservative Blue Dog Democrats group could not agree on a compromise late Tuesday after more than six hours of discussion, complicating efforts to have legislation on the House floor before the August recess.
Sexual Health

Combined Data From Four Large-Scale Studies Demonstrate The Efficacy And Tolerability Of Seroquel In Bipolar Depression

Results presented today at the 162nd American Psychiatric Association (APA) congress in San Francisco, CA, demonstrated the efficacy and tolerability of SEROQUEL® (quetiapine fumarate) for treating depressive episodes in bipolar disorder, including the difficult-to-treat bipolar II patient population.1,2 The data are from combined analyses of four large-scale clinical trials to examine SEROQUEL as a treatment for depressive episodes associated with bipolar I and II disorders. SEROQUEL and SEROQUEL XR™, a once-daily, extended-release formulation of SEROQUEL, is one of the most widely studied atypical antipsychotic in bipolar depression and the only agent approved as monotherapy to treat the spectrum of mood episodes associated with bipolar disorder. "Bipolar disorder is a chronic illness with patients experiencing severe debilitating mood swings. Patients spend a majority of their time ill in the depressed phase of the illness. These important findings confirm that SEROQUEL is an effective agent for the treatment of bipolar depression, and particularly encouraging are the results in bipolar II patients who historically have not responded well to treatment," said Professor Alan Young of the Department of Psychiatry, University of British Columbia, Vancouver, Canada. Results from a combined analysis of all patients with bipolar I or II disorder (n=2593) demonstrated that SEROQUEL monotherapy was significantly more effective than placebo for treating depressive episodes associated with bipolar disorder as measured by improvements in the Montgomery-ãºsberg Depression Rating Scale (MADRS) total score (PAbout SEROQUEL and SEROQUEL XR Launched in 1997, it is estimated that SEROQUEL has been prescribed to more than 22 million patients worldwide. SEROQUEL has been approved in 94 countries for schizophrenia, 92 countries for bipolar mania, in 41 countries for bipolar depression and in 6 countries for bipolar maintenance. SEROQUEL XR has been approved in 53 countries for schizophrenia, 19 countries for bipolar mania, in 20 countries for bipolar depression, in 9 markets for bipolar maintenance, in 1 market for Major Depressive Disorder (MDD), and in 1 market for Generalised Anxiety Disorder (GAD). References 1. Calabrese JR, et al. The efficacy of quetiapine monotherapy in bipolar depression: combined data from the BOLDER and EMBOLDEN studies. Presented at the American Psychiatric Association, San Francisco, CA, USA, 16-21 May, 2009. 2. Young AH, et al. The efficacy of quetiapine monotherapy in bipolar II depression: combined data from the BOLDER and EMBOLDEN studies. Presented at the American Psychiatric Association, San Francisco, CA, USA, 16-21 May, 2009. 3. Suppes T, et al. Effectiveness of the new extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression (trial D144CC00002). Presented at the Eighth International Review of Bipolar Disorder Conference, Copenhagen, Denmark, 14-16 April, 2008. AstraZeneca


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009